Triple-Negative Breast Cancer | Clinical Trials | Oropharyngeal Cancer, Cancer Information Highlights, 05/26/2021

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
New from NCI
Targeted Therapy Approved for Triple-Negative Breast Cancer
2 circles representing breast cancer cells, one triple-negative breast cancer and the other most breast cancer cells. The triple-negative breast cancer cells don't have estrogen receptors (ER), progesterone receptors (PR), or large amounts of the HER2 protein on their surface.   The Food and Drug Administration (FDA) has fully approved sacituzumab govitecan (Trodelvy) for some people with triple-negative breast cancer. Sacituzumab consists of an antibody coupled to the chemotherapy drug irinotecan (Camptosar). The antibody binds to breast cancer cells, bringing the chemotherapy to those cells.
Clinical Trials Help Build the Future of Medicine
Dr. Raymond Osarogiagbon   Read how Dr. Raymond Osarogiagbon helps people in Memphis find cancer treatment options through clinical trials and how Dr. Linda Robertson, Patty Andres-Sanmartin, and CeCe Williams help Pittsburgh’s underserved patients navigate cancer.
Looking for Ways to Do Less Harm When Treating Oropharyngeal Cancer

Learn more about oropharyngeal cancer, a type of head and neck cancer, and efforts to treat it with less intense treatment. Usual treatments for this cancer often cause severe side effects.
Discovery of Tumor Suppressor Suggests New Ways To Treat Cancer

Researchers have shown that the loss of a protein called AMBRA1 can cause tumors to form in mice and is linked with worse outcomes in some people with cancer. The loss of AMBRA1 also reduces how well certain drugs work on the tumors, so new research could lead to better treatment strategies.

PDQ Updates
Malignant Mesothelioma

We’ve revised our malignant mesothelioma summary with updated information about treatment for stages II, III, and IV disease.
FDA Approvals
New Treatment for Non-Hodgkin Lymphoma

We’ve added a new drug summary for loncastuximab tesirine-lpyl (Zynlonta). This drug was recently approved by FDA to treat adults with certain types of B-cell non-Hodgkin lymphoma that came back or did not get better after other treatment.
Also of Interest
NCI’s Clinical Trials Programs

Learn why clinical trials are vital to making progress against cancer, how new knowledge about cancer is changing clinical trials, and how NCI programs make a difference.

Time to Be Smokefree offers science-based tools and support to help smokers quit. It includes links to tailored information for veterans, women, teens, Spanish-speakers, and people over 60 who want to be smokefree.

Contact Us for Help

Information specialists at NCI’s Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.